Newswire (Published: Thursday, March 19, 2020, Received: Thursday, March 19, 2020, 6:02:40 PM CDT)

Word Count: 954

2020 MAR 19 (NewsRx) -- By a News Reporter-Staff News Editor at Clinical Trials Daily -- A new study on Oncology - Prostate Cancer is now available. According to news reporting originating in Orsay, France, by NewsRx journalists, research stated, “Importance Both alpha-emitting and beta-emitting bone-targeted radioisotopes (RIs) have been developed to treat men with metastatic castration-resistant prostate cancer (CRPC). Only 1 phase 3 randomized clinical trial has demonstrated an overall survival (OS) benefit from an alpha-emitting RI, radium 223 (Ra-223), vs standard of care.”

Funders for this research include Bayer, Ligue Nationale Contre le Cancer.

The news reporters obtained a quote from the research from the University of Paris Sud, “Yet no head-to-head comparison has been done between alpha-emitting and beta-emitting RIs. To assess OS in men with bone metastases from CRPC treated with bone-targeted RIs and to compare the effects of alpha-emitting RIs with beta-emitting RIs. PubMed, Cochrane Library, ClinicalTrials.gov, and meeting proceedings between January 1993 and June 2013 were reviewed. Key terms included randomized trials, radioisotopes, radiopharmaceuticals, and prostate cancer. Data were collected, checked, and analyzed from February 2017 to October 2018. Selected trials included patients with prostate cancer, recruited more than 50 patients from January 1993 to June 2013, compared RI use with no RI use (placebo, external radiotherapy, or chemotherapy), and were randomized. Patients were diagnosed with histologically proven prostate cancer and disease progression after both surgical or chemical castration and have evidence of bone metastasis. Nine randomized clinical trials were identified as eligible, but 3 were excluded for insufficient data. Data Extraction and Synthesis Individual patient data were requested for each eligible trial, and all data were checked with a standard procedure. The log-rank test stratified by trial was used to estimate hazard ratios (HRs), and a similar fixed-effects (FE) model was used to estimate odds ratios (ORs). The between-trial heterogeneity of treatment effects was evaluated by Cochran test and I-2 and was accounted by a random-effects (RE) model. Main Outcomes and Measures Overall survival; secondary outcomes were symptomatic skeletal event (SSE)-free survival and adverse events. Based on 6 randomized clinical trials including 2081 patients, RI use was significantly associated with OS compared with no RI use (HR, 0.86; 95% CI, 0.77-0.95; P = .004) with high heterogeneity (chi(2)(5) = 24.46; P< .001; I-2 = 80%), but this association disappeared when using an RE model (HR, 0.80; 95% CI, 0.61-1.06; P = .12; tau(2) = 0.08). The heterogeneity is explained both by the type of RI and by the inclusion of 2 outlier trials that included 275 patients; the OS benefit was significantly higher with the alpha-emitting RI Ra-223 (HR, 0.70; 95% CI, 0.58-0.83) but not significant with the beta-emitting RI strontium-89 (HR, 0.96; 95% CI, 0.84-1.10) (P for interaction = .004). Excluding the outlier trials led to an overall HR of 0.82 (95% CI, 0.73-0.92; P< .001) (between-trial heterogeneity: chi(2)(3) = 6.51; P = .09; I-2 = 54%) using an FE model and an HR of 0.80 (95% CI, 0.65-0.99; P = .04; tau(2) = 0.02) using an RE model. The HR for SSE-free survival was 0.81 (95% CI, 0.69-0.93; P = .004) (between-trial heterogeneity: chi(2)(3) = 6.71; P = .08; I-2 = 55%) when using an FE model and was 0.76 (95% CI, 0.58-1.01; P = .06; tau(2) = 0.04) when using an RE model. There were more hematological toxic effects with RI use compared with no RI use (OR, 1.48; 95% CI, 1.17-1.88; P = .001). Conclusions and Relevance In metastatic CRPC, a significant improvement of OS and SSE-free survival was obtained with bone-targeted alpha-emitting but not beta-emitting RIs. Caution is necessary for generalizability of these results, given the between-trial heterogeneity. This meta-analysis of randomized clinical trials assesses overall survival in men with bone metastases from castration-resistant prostate cancer treated with bone-targeted radioisotopes and compares the effects of alpha-emitting with beta-emitting radioisotopes. Question What is the benefit of bone-targeted radioisotope (RI) use in metastatic castration-resistant prostate cancer, and is there any difference between alpha-emitting and beta-emitting RIs? Finding This meta-analysis of individual patient data was based on 6 randomized clinical trials including 2081 patients that compared RI use with no RI use study arms with no overall significant difference. While an alpha-emitting RI (radium 223) was significantly associated with higher overall survival and higher symptomatic skeletal event-free survival, a beta-emitting RI (strontium-89) was not associated with these outcomes.”

According to the news reporters, the research concluded: “Meaning This meta-analysis suggests a benefit of alpha-emitting RIs but not of beta-emitting RIs for overall survival and symptomatic skeletal event-free survival, although caution is necessary for generalizability of these results, given the between-trial heterogeneity.”

For more information on this research see: Overall Survival In Men With Bone Metastases From Castration-resistant Prostate Cancer Treated With Bone-targeting Radioisotopes a Meta-analysis of Individual Patient Data From Randomized Clinical Trials. JAMA Oncology, 2020;6(2):206-216. JAMA Oncology can be contacted at: Amer Medical Assoc, 330 N Wabash Ave, Ste 39300, Chicago, IL 60611-5885, USA.

Our news correspondents report that additional information may be obtained by contacting G. Le Teuff, University of Paris Sud, Orsay, France. Additional authors for this research include S. Terrisse, K. Fizazi, E. Karamouza, J.P. Pignon, C.C. Parker, A.O. Sartor, N.D. James, S. Pirrie, L. Collette, B.F. Tombal, J. Chahoud, S. Smeland and B. Erikstein.

The direct object identifier (DOI) for that additional information is: https://doi.org/10.1001/jamaoncol.2019.4097. This DOI is a link to an online electronic document that is either free or for purchase, and can be your direct source for a journal article and its citation.

(Our reports deliver fact-based news of research and discoveries from around the world.)

Industries

Healthcare
      Medical Devices
            Medical Treatment Devices
                  Radiosurgery Devices
Manufacturing
      Medical Device Manufacturing
            Medical Devices
                  Medical Treatment Devices
                        Radiosurgery Devices

Places

North America
Western Europe
France
United States
Americas
Europe
Illinois
Chicago

Subjects

Science and Technology
      Scientific Research
            Medical Research
Health and Wellness
      Medical Conditions and Diseases
            Cancer
                  Prostate Cancer
            Men's Health Issues
                  Prostate Cancer
      Health Sciences
            Medical Research
            Pharmaceutical Development
      Treatments and Therapies
            Medicinal Drugs